[ad_1]
Corona 19 vaccine developed jointly by the American pharmaceutical company Pfizer and the German Bioentech▶ Click here to enlarge the view
The New York Times (NYT) reported on the 22nd (local time) that the US administration of Donald Trump is approaching a contract to buy tens of millions of doses of a new vaccine against the coronavirus infection (Corona 19) next year of Pfizer, a pharmaceutical company.
The contract, to be announced on the 23rd, is expected to include a US government order to make it easier for Pfizer to source vaccine raw materials, a source familiar with the matter said.
Pfizer will supply all of its additional production to the US government in exchange for receiving more raw materials.
Initially, the Trump administration requested that 100 million doses of vaccine be supplied in the second quarter of next year, but Pfizer is known to have a difficult time saying that more than 70 million doses can be produced if there are many raw materials for the vaccine. .
Consequently, the Trump administration decided to apply the Defense Goods Production Act (DPA) to help Pfizer source more of the nine specialty products it needs to make the Corona 19 vaccine.
Pfizer asked the US government to help source additional vaccine raw materials beginning in September, but the Trump administration did not respond due to support for Modena and other companies funded by the “ High Speed Operations ” program. ” It was said that it was.
An additional contract with Pfizer is expected to allow the United States government to vaccinate nearly 200 million Americans in the first half of next year.
According to the NYT, the Trump administration agreed to receive 100 million doses of the Pfizer vaccine during the first quarter of next year through a contract in July, and 100 million doses of the Modena vaccine each in the first and second quarters. .
This means that the two companies have secured the number of vaccines that 150 million Americans can inoculate, as the vaccine must be given twice to gain immunity.
There are a total of 260 million Americans in the age range (Pfizer 16 and older, Modena 18 and older) eligible for vaccination. This means that 110 million of them will not be able to receive the vaccine during the first half of next year.
In this situation, if Pfizer supplies tens of thousands of additional vaccines in the second quarter, and the United States Food and Drug Administration (FDA) approves the use of vaccines from other companies that have already been contracted early next year , most Americans of vaccination age will be vaccinated during the first half. The NYT predicted that it is likely to be affected.
[연합뉴스]
Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
